Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Search
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
Giving Life a Chance
The Angels initiative honours stroke units and the everyday heroes making a difference for stroke patients
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together
World Heart Day 2021
Cardiovascular diseases, including heart disease, are the leading cause of death and disability worldwide and are closely linked to kidney and metabolic diseases.
Regional experts highlight need for coordinated, collaborative efforts in stroke care through
Regional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital unitsRegional experts highlight need for coordinated, collaborative efforts in stroke care through dedicated hospital units
Boehringer launches the Treatment for Three Interstitial Lung Diseases in Qatar
• This is the first time that an approved antifibrotic medication will be available for ILD patients residing in Qatar
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines
Boehringer Ingelheim commences local production of first batch of antihypertensive medicines in Algeria
Boehringer Ingelheim unites dermatologists to discuss the management of Generalized Pustular Psoriasis (GPP)
The ‘GPP Summit, discussed latest research and advances in the management of GPP to help improve patient outcomes across Saudi Arabia, and the United Arab Emirates.
Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts
Boehringer Ingelheim hosted the ‘CRM Summit’ to facilitate exchanges and discussions on the latest advances in the management of cardiovascular, renal, and metabolic diseases to help improve patient outcomes across India, the Middle East and Africa
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
Combination Therapy
We are designing smart combinations of immuno-oncology and cancer cell directed therapies to maximise the benefit to our patients.
Boehringer Ingelheim Convenes Educational Meetings to Empower Over 300 Regional Experts with Latest Heart Failure Advances
• Boehringer Ingelheim hosted ‘Heart Talks’and ‘MEDEX’ to discuss latest updates in heart failure management and help improve patient outcomes across India, the Middle East and Africa
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Translational Medicine in Immunology
Find out how translational medicine is helping bring transformational therapies to patients
COPD Patient brochure
Boehringer Ingelheim announces Reach Africa Access Healthcare programs outcomes
Boehringer Ingelheim, announces “In Reach Africa” Access to Healthcare programs outcomes
Micardis®
Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A
The UAE MOHAP Approves the First and Only Therapy for the Treatment of Adult Generalized Pustular Psoriasis Flares
The first treatment of its kind in the UAE by Boehringer Ingelheim is the only FDA and EMA-approved medication used to treat GPP flares in adult patients and works to help block a source of inflammation that may cause GPP flares
Clinical Collaborations
Clinical Collaborations
Research Collaborations
Research Collaborations
Spotlight on GPP
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.